by William Newton in Texas Alkermes’ ALKS-3831 for schizophrenia and bipolar disorder has evoked mixed expert forecasts for how a Food and Drug Administration (FDA) Advisory Committee (AdCom) meeting on...
Foreseeing a global pandemic is not in any business leader’s job description. But perhaps the most vital skill for today’s…
Marinus Pharmaceuticals is set to start patient enrolment in the Phase III RAISE clinical trial of ganaxolone for the treatment of refractory status epilepticus (RSE).…
OncoImmune has reported that Saccovid reduced the risk of death and aided faster recovery in patients with severe or critical Covid-19 in Phase III SAC-COVID…
US-based biotechnology firm Novavax has started the first Phase III clinical trial of its potential Covid-19 vaccine, NVX-CoV2373, in the…
Vifor Pharma has reported data from the AFFIRM-AHF clinical trial of Ferinject (intravenous ferric carboxymaltose) in iron-deficient patients hospitalised due…
Swiss-based biopharmaceutical company AC Immune and Genentech have said that Phase II TAURIEL trial of semorinemab failed to meet the…
Johnson & Johnson (J&J) has initiated the pivotal Phase III ENSEMBLE clinical trial of its Covid-19 vaccine candidate, JNJ-78436735 (Ad26.COV2.S),…
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of…
A total of 29 million confirmed cases of Covid-19 have been reported worldwide, with the number of deaths approaching one million: 925,000 to be exact, as of 15 September 2020.…
by Ayisha Sharma in London. Subcutaneous (SC) formulations of Apellis Pharmaceuticals’ pegcetacoplan and Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz) are unlikely to have widespread uptake in first-line paroxysmal nocturnal haemoglobinuria (PNH) despite…
EASD 2020: Results from the TIMES 3 trial – efficacy and safety of imeglimin in combination with insulin in Japanese patients with type 2 diabetes
At the 56th annual European Association for the Study of Diabetes (EASD) 2020 meeting, positive results have been discussed for the novel oral hypoglycemic drug imeglimin, which is currently under…